Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

– Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 –

– On track to initiate similarly-designed Phase 2 study in patients with COPD imminently –

Read more at globenewswire.com